Seven weeks after the FDA approved Merck’s LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, 78% of surveyed US physicians already knew the brand. Use was far more selective. It made up 6% of recent PCSK9-pathway starts. ZoomRx paired an awareness, trial and usage (ATU) survey with a patient chart analysis (PCA) to see why, and the answer sits in three places: patient requests, plan coverage, and the outcomes evidence physicians are still waiting for.
Key findings at a glance
- Awareness came fast. 78% of physicians knew LIPFENDRA, above ZoomRx’s 67% benchmark for a top 10 manufacturer’s launch at three months.
- Patients drove the starts. 72% of LIPFENDRA patients had asked for an oral option or for the brand by name.
- Physicians understate preference. They gave route of administration about 7 of 100 importance points, yet oral route was a top reason in 44% of LIPFENDRA choices.
- Coverage set the limit. Of 20 patients who went to Repatha instead, 11 did so because the plan favored Repatha.
- Stable injectable patients are staying put. Only 7% of 60 were rated very or extremely likely to switch within six months.
Why 2026 is a reset year for hyperlipidemia treatment
Four events since March 2026 changed how physicians weigh advanced lipid-lowering options.
|
Date |
What happened |
Why it matters |
|
13 Mar 2026 |
The 2026 ACC/AHA dyslipidemia guideline brought back LDL-C goals (<100, <70 and <55 mg/dL by risk) and replaced the Pooled Cohort Equations with PREVENT |
Epic Research estimates eligibility for lipid-lowering therapy among adults without ASCVD rises from 41% to 55% |
|
16 Jul 2026 |
FDA approved LIPFENDRA, which cut LDL-C by 56% vs. placebo at week 24 |
PCSK9 lowering without an injection, at roughly half the list price of other PCSK9 products. The CORALreef Outcomes trial is ongoing. |
|
4 Sep 2026 |
Novartis reported that Lp(a)HORIZON missed its primary endpoint |
Lowering a biomarker did not reduce events, which raises the evidence bar for every new agent |
|
21 Sep 2026 |
The European Commission approved obicetrapib, an oral CETP inhibitor, alone and with ezetimibe |
A second oral, non-statin class is now approved outside the US |
How ZoomRx measured physician adoption
The pulse ran from 31 August to 9 September 2026. 46 US physicians answered the awareness questions and 34 qualified for the main survey, mostly endocrinologists, cardiologists, and family physicians in community practice. They also described 85 recent patient charts: 25 LIPFENDRA, 50 Repatha, and 10 Leqvio. AI-moderated interviews probed trade-offs, access, and switching.
Finding 1: Patients asked for a pill far more often than for the brand
Of 25 LIPFENDRA patients, 18 (72%) had asked for an oral option or for the brand by name. Requests for “a pill” outnumbered requests for LIPFENDRA itself, 60% to 12%. Across all 85 charts, 39% of patients voiced a preference, and physicians honored 28 of 33 requests (85%).
“The patient had a preference for being on oral therapy. I had originally prescribed an injectable. The patient had no interest in it.” Cardiologist, ZoomRx pulse
Finding 2: What physicians say drives choice and what their charts show are far apart
In the survey, physicians gave LDL-C lowering 25 of 100 importance points and outcomes evidence 23. Route of administration got about 7 and patient preference about 1. In the charts, oral route was among the top reasons for 44% of LIPFENDRA choices. (Why physician rankings and patient charts tell different stories explains what this gap means for research planning.)
Finding 3: The oral option is widening the pool
Physicians said 77% of their LIPFENDRA starts had no prior PCSK9-pathway therapy. LIPFENDRA patients were younger than Repatha patients (mean age 53 vs. 60), 60% were in primary prevention, and 88% were commercially insured. (Which patients a new drug reaches first profiles these patients in detail.)
Finding 4: Coverage and outcomes evidence set the ceiling
LIPFENDRA was considered and not chosen for 29 patients, and 20 of them received Repatha. For 11 of those 20, the plan favored Repatha and LIPFENDRA would have cost the patient more. Eight of the 11 were on Medicare or Medicaid.
Outcomes data is the other gate. 63% of physicians asked (n = 27) want LIPFENDRA outcomes data before broader use, most of all in secondary prevention.
“If they have the cardiovascular trials, that’s really where it will… become a huge hit.” Physician, ZoomRx pulse
Finding 5: Stable injectable patients are staying put
Across 60 patients stable on Repatha or Leqvio, physicians rated 7% very or extremely likely to be switched to LIPFENDRA within six months and 43% not at all likely. These are expectations, not observed switches. A switch usually needs a trigger: a patient asking for a pill, injection fatigue, a coverage change, or LDL-C that stays above goal.
Where practice and the 2026 guideline agree
|
2026 guideline |
What the pulse shows |
Read |
|
LDL-C goals return (<70 high-risk primary prevention, <55 very-high-risk ASCVD) |
Physicians set goals of <55 to 70 mg/dL; mean chart goals were 62 to 68 |
Aligned |
|
Escalate faster and combine therapies |
Patients arrived about 50 to 60 mg/dL above goal; 52% of LIPFENDRA starts came straight from a statin with or without ezetimibe |
Partly aligned |
|
Favor therapies with outcomes evidence |
63% want LIPFENDRA outcomes data |
Aligned |
|
Patient preference informs the add-on choice |
Preference got about 1 of 100 stated points, yet 72% had asked for a pill or the brand |
Gap |
What to watch next
- Outcomes readouts: CORALreef Outcomes for LIPFENDRA and PREVAIL for obicetrapib.
- Formulary coverage: most coverage-driven losses were in Medicare and Medicaid plans, where guideline-driven eligibility is growing.
- Unprompted switching: whether physicians start offering the pill to stable injectable patients without a request.
- More oral options: AstraZeneca’s oral PCSK9 candidate AZD0780 is in a Phase III outcomes trial, so demand tied to the route will face competition.
Read the full case study
The case study, Hyperlipidemia treatment decisions in 2026, sets out every figure with its base, the guideline comparison, and the patient-level detail behind each finding. Read the full case study →
To run the same read on your own brand, see how ZoomRx pairs ATU brand tracking with Patient Chart Audits in one panel and one wave.
Source for all ZoomRx figures: ZoomRx hyperlipidemia pulse, fielded 31 Aug to 9 Sep 2026 (ATU n = 46 / 34; PCA n = 85 charts).
LIPFENDRA is a registered trademark of Merck Sharp & Dohme LLC. Repatha is a registered trademark of Amgen Inc. LEQVIO is a registered trademark of Novartis AG. ZoomRx is not affiliated with, and this paper is not sponsored or endorsed by these companies.
Frequently asked questions
